Abstracts tagged "Idiopathis Inflammatory Myopathies (IIM)"

Abstract Number: 1351 • 2018 ACR/ARHP Annual Meeting
In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies
Iazsmin Bauer Ventura¹, Daniel Reilly², Peter Pytel³ and Vladimir Liarski², ¹Medicine, Section of Rheumatology, University of Chicago, Chicago, IL, ²Medicine, Section of Rheumatology, University of Chicago, chicago, IL, ³Medicine, Section of Pathology, University of Chicago, chicago, IL
Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are the largest number of acquired and potentially treatable muscle disorders. Nevertheless, there are currently no FDA or EMA-approved…
Abstract Number: 2163 • 2018 ACR/ARHP Annual Meeting
Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years
Yoon-Kyoung Sung¹, Hyoungyoung Kim², Jisun Myung³, Eunwoo Nam³, Sun-Young Jung⁴, Eun Jin Jang⁵, Dae-Hyun Yoo⁶ and Soo-Kyung Cho², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Korea, Republic of (South), ⁴College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), ⁵Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), ⁶Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Prevalence and Incidence of idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study over 10 yearsYoon-Kyoung Sung1, Hyoungyoung Kim1, Jisun Myung2, Eunwoo Nam2, Sun-young Jung3,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].